For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
Before You Checkout
Bundle complementary compounds together — priced below buying each separately.
Recovery Stack
Tissue repair & regeneration research
Growth Axis Stack
Growth-hormone-axis research
Longevity Stack
Cellular & metabolic longevity
Research Comparison
Tirzepatide and GLP-3RT are both synthetic incretin-receptor peptides, differing in how many receptors they engage. Tirzepatide is a dual agonist of the GIP and GLP-1 receptors, while GLP-3RT is a triple agonist that adds glucagon-receptor (GCGR) activity. Both are studied in vitro for incretin receptor pharmacodynamics and downstream cAMP signaling.
| Attribute | Tirzepatide | GLP-3RT |
|---|---|---|
| Receptor targets | GIP + GLP-1 | GLP-1 + GIP + GCGR |
| Agonist type | Dual incretin agonist | Triple agonist |
| Distinguishing mechanism | Dual-incretin activation | Adds glucagon-receptor (GCGR) activity |
| Research focus | Dual-incretin signaling, glucose metabolism | Multi-receptor pharmacodynamics |
Tirzepatide engages two incretin receptors (GIP and GLP-1), while GLP-3RT engages three by adding glucagon-receptor (GCGR) activity. Both are studied in vitro for incretin receptor binding and downstream cAMP signaling.